Search Results - Carlos Gomez-Roca

  • Showing 1 - 7 results of 7
Refine Results
  1. 1

    315 W0180 novel anti-VISTA antibody: Rationale for target patient population and first-in-human trial design in monotherapy and in combination with anti-PD1 antibody by Aurélien Marabelle, Carlos Gomez-Roca, Pierre Ferre, Eric Chetaille, Aurelie Petain, Celine Thuilliez, Isabelle Vandenberghe, Francisco Cruzalegui, Asmaa Boudribila, Mariya Pavlyuk

    Published in Journal for ImmunoTherapy of Cancer (2020-11-01)
    Article


  2. 2

    A double-edged sword: unusual multiple severe infections with pralsetinib: a case report and literature review by François Poumeaud, Marion Jaffrelot, Carlos Gomez-Roca, Iphigénie Korakis, Giulia Leonardi, Marine Joly, Julien Mazières, Rosine Guimbaud, Nadim Fares, Nadim Fares, Emily Alouani, Emily Alouani

    Published in Frontiers in Medicine (2024-07-01)
    Get full text
    Article


  3. 3

    1521 Identification of microenvironment features associated with primary resistance to anti-PD-1/PD-L1 + antiangiogenesis in gastric cancer: a joint analysis of the REGOMUNE and RE... by Kohei Shitara, Antoine Adenis, Antoine Hollebecque, Antoine Italiano, Shohei Koyama, Hiroyoshi Nishikawa, Carlos Gomez-Roca, Philippe Cassier, Alban Bessede, Jean-Philippe Metges, Sophie Cousin, Jean-Philippe Guégan, Shota Fukuoka, Lola-Jade Palmieri

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  4. 4

    721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumor... by Anne Goubier, Neeltje Steeghs, Carlos Gomez-Roca, Philippe Cassier, Elena Fernandez, Eelke Gort, Hilde De Winter, Vaia Stavropoulou, Nina Stojcheva, Paul Baverel, Jennifer Krieg, Kyriaki Ioannou, Ana Maria Florescu, Lea Hoenig, Bruno Baud-Berthier, Michael P Sanderson, Vladimir Kirkin, Philippe Legenne

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  5. 5

    PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells by Camille-Charlotte Balança, Anna Salvioni, Clara-Maria Scarlata, Marie Michelas, Carlos Martinez-Gomez, Carlos Gomez-Roca, Victor Sarradin, Marie Tosolini, Carine Valle, Frédéric Pont, Gwénaël Ferron, Laurence Gladieff, Sébastien Vergez, Agnès Dupret-Bories, Eliane Mery, Philippe Rochaix, Jean-Jacques Fournié, Jean-Pierre Delord, Christel Devaud, Alejandra Martinez, Maha Ayyoub

    Published in JCI Insight (2021-01-01)
    Get full text
    Article


  6. 6

    Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients by Jean-Marie Michot, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Dmitriy Zamarin, Jean-Pascal Machiels, Anna-Maria Jegg, Dominik Rüttinger, Konstanty Korski, Jean-Pierre Delord, Carlos Gomez-Roca, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Michael A Cannarile, Carl Watson, Galina Babitzki, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Randolph Christen, Philippe Cassier

    Published in Journal for ImmunoTherapy of Cancer (2020-10-01)
    Get full text
    Article


  7. 7

    Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study by Yonina R. Murciano-Goroff, Antoine Hollebecque, Rebecca S. Heist, Philippe A. Cassier, Ji-Youn Han, So Yeon Kim, Joshua K. Sabari, Diego Tosi, Adrian Sacher, Timothy F. Burns, Toshio Shimizu, Natraj Reddy Ammakkanavar, Alexander Spira, Carlos Gomez-Roca, Amita Patnaik, Rasha Cosman, J. Nicholas Bodor, Misako Nagasaka, Arthur Xintian You, Samuel C. McNeely, Raimund Peter, Aaron Fink, Aaron Chen, Geoffrey R. Oxnard, Melinda D. Willard, Yasutoshi Kuboki, Takafumi Koyama

    Published in Nature Communications (2026-03-01)
    Get full text
    Article


Search Tools: